

Marc Brisson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10669626/publications.pdf>

Version: 2024-02-01

88
papers

6,672
citations

66343

42
h-index

64796

79
g-index

90
all docs

90
docs citations

90
times ranked

6094
citing authors

#	ARTICLE	IF	CITATIONS
1	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. <i>Lancet, The</i> , 2019, 394, 497-509.	13.7	630
2	Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 565-580.	9.1	556
3	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 575-590.	13.7	421
4	Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 781-789.	9.1	343
5	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 591-603.	13.7	321
6	The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. <i>Cmaj</i> , 2010, 182, 1731-1736.	2.0	230
7	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health, The</i> , 2016, 1, e8-e17.	10.0	210
8	Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. <i>The Lancet Global Health</i> , 2014, 2, e406-e414.	6.3	194
9	The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. <i>Vaccine</i> , 2007, 25, 5399-5408.	3.8	161
10	Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. <i>Value in Health</i> , 2012, 15, 828-834.	0.3	152
11	Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. <i>Vaccine</i> , 2007, 25, 8326-8337.	3.8	125
12	Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model-Based Analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1712-1723.	6.3	119
13	Dynamic Transmission Modeling. <i>Medical Decision Making</i> , 2012, 32, 712-721.	2.4	117
14	Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models. <i>Medical Decision Making</i> , 2011, 31, 675-692.	2.4	115
15	Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. <i>Journal of Infectious Diseases</i> , 2011, 204, 372-376.	4.0	110
16	Predictors of Postherpetic Neuralgia Among Patients With Herpes Zoster: A Prospective Study. <i>Journal of Pain</i> , 2010, 11, 1211-1221.	1.4	106
17	Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty. <i>American Journal of Epidemiology</i> , 2007, 165, 762-775.	3.4	102
18	Modeling Cervical Cancer Prevention in Developed Countries. <i>Vaccine</i> , 2008, 26, K76-K86.	3.8	102

#	ARTICLE	IF	CITATIONS
19	Evidence of synergistic relationships between <scp>HIV</scp> and Human Papillomavirus (<scp>HPV</scp>): systematic reviews and meta-analyses of longitudinal studies of <scp>HPV</scp> acquisition and clearance by <scp>HIV</scp> status, and of <scp>HIV</scp> acquisition by <scp>HPV</scp> status. <i>Journal of the International AIDS Society</i> , 2018, 21, e25110.	3.0	96
20	Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries. <i>Public Health Genomics</i> , 2009, 12, 343-351.	1.0	95
21	Modelling the Epidemiology of Infectious Diseases for Decision Analysis. <i>Pharmacoeconomics</i> , 2011, 29, 371-386.	3.3	95
22	Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. <i>Vaccine</i> , 2010, 28, 3385-3397.	3.8	83
23	The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. <i>Hum Vaccin</i> , 2008, 4, 238-245.	2.4	81
24	The psychosocial impact of an abnormal cervical smear result. <i>Psycho-Oncology</i> , 2012, 21, 1071-1081.	2.3	80
25	Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. <i>Vaccine</i> , 2010, 28, 5473-5484.	3.8	79
26	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. <i>Emerging Infectious Diseases</i> , 2016, 22, 1732-1740.	4.3	77
27	Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv282.	6.3	74
28	Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. <i>International Journal of Cancer</i> , 2014, 134, 2264-2268.	5.1	72
29	A Prospective Study of the Herpes Zoster Severity of Illness. <i>Clinical Journal of Pain</i> , 2010, 26, 656-666.	1.9	71
30	The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study. <i>Sexually Transmitted Diseases</i> , 2011, 38, 949-956.	1.7	68
31	Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. <i>Vaccine</i> , 2018, 36, 4806-4815.	3.8	68
32	The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018. <i>Sexually Transmitted Diseases</i> , 2021, 48, 215-221.	1.7	68
33	Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. <i>BMJ, The</i> , 2015, 350, g7584-g7584.	6.0	62
34	Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. <i>Vaccine</i> , 2020, 38, 1302-1314.	3.8	61
35	Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. <i>Annals of Internal Medicine</i> , 2020, 172, 22.	3.9	60
36	HEALTH-RELATED QUALITY OF LIFE LOST TO ROTAVIRUS-ASSOCIATED GASTROENTERITIS IN CHILDREN AND THEIR PARENTS. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 73-75.	2.0	59

#	ARTICLE	IF	CITATIONS
37	Global elimination of cervical cancer as a public health problem. <i>Lancet Oncology</i> , The, 2019, 20, 319-321.	10.7	58
38	Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. <i>Cmaj</i> , 2007, 177, 464-468.	2.0	51
39	Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. <i>Vaccine</i> , 2014, 32, 5845-5853.	3.8	49
40	Estimated Prevalence and Incidence of Disease-Associated Human Papillomavirus Types Among 15- to 59-Year-Olds in the United States. <i>Sexually Transmitted Diseases</i> , 2021, 48, 273-277.	1.7	48
41	Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2005, 29, 544-551.	1.8	44
42	Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study. <i>Vaccine</i> , 2012, 30, 2047-2050.	3.8	43
43	Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. <i>Vaccine</i> , 2013, 31, 3863-3871.	3.8	43
44	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100184.	4.5	41
45	Guidelines for multi-model comparisons of the impact of infectious disease interventions. <i>BMC Medicine</i> , 2019, 17, 163.	5.5	39
46	Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. <i>The Lancet Global Health</i> , 2020, 8, e536-e544.	6.3	39
47	Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. <i>Lancet Public Health</i> , The, 2016, 1, e66-e75.	10.0	37
48	Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. <i>Journal of Infectious Diseases</i> , 2016, 214, 685-688.	4.0	37
49	Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective Community-Based Study. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 397-404.	1.9	36
50	Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women—implications for vaccination. <i>Cancer Causes and Control</i> , 2009, 20, 1387-1396.	1.8	35
51	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1598-1610.	9.1	34
52	Varicella Vaccine and Shingles. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 2211-2212.	7.4	34
53	Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 213, 1694-1700.	4.0	32
54	Sociodemographic Inequalities in Sexual Activity and Cervical Cancer Screening: Implications for the Success of Human Papillomavirus Vaccination. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 641-652.	2.5	30

#	ARTICLE	IF	CITATIONS
55	The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation. <i>Journal of Infectious Diseases</i> , 2017, 216, 1205-1209.	4.0	28
56	Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. <i>Sexually Transmitted Infections</i> , 2011, 87, 41-43.	1.9	27
57	Vaccination against herpes zoster in developed countries. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1177-1184.	3.3	25
58	Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts. <i>BMC Medicine</i> , 2013, 11, 23.	5.5	24
59	Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0163880.	2.5	24
60	Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia. <i>Clinical Infectious Diseases</i> , 2007, 45, 1527-1529.	5.8	23
61	Inequalities in Human Papillomavirus (HPV)-Associated Cancers: Implications for the Success of HPV Vaccination. <i>Journal of the National Cancer Institute</i> , 2013, 105, 158-161.	6.3	23
62	Loss of quality of life associated with genital warts: baseline analyses from a prospective study. <i>Sexually Transmitted Infections</i> , 2011, 87, 209-215.	1.9	22
63	Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?. <i>Vaccine</i> , 2014, 32, 3237-3242.	3.8	21
64	Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. <i>Value in Health</i> , 2018, 21, 1250-1258.	0.3	21
65	Estimating the Number Needed to Vaccinate to Prevent Herpes Zoster-related Disease, Health Care Resource Use and Mortality. <i>Canadian Journal of Public Health</i> , 2008, 99, 383-386.	2.3	20
66	Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. <i>European Journal of Pain</i> , 2011, 15, 1100-1106.	2.8	20
67	Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior. <i>Emerging Infectious Diseases</i> , 2016, 22, 18-23.	4.3	20
68	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. <i>International Journal of Cancer</i> , 2016, 139, 510-517.	5.1	19
69	Changing Inequalities in Cervical Cancer: Modeling the Impact of Vaccine Uptake, Vaccine Herd Effects, and Cervical Cancer Screening in the Post-Vaccination Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 276-285.	2.5	15
70	Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions. <i>American Journal of Epidemiology</i> , 2016, 184, 873-883.	3.4	15
71	Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada. <i>Vaccine</i> , 2016, 34, 1874-1880.	3.8	15
72	Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. <i>International Journal of Cancer</i> , 2018, 143, 317-323.	5.1	15

#	ARTICLE	IF	CITATIONS
73	Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. <i>Cmaj</i> , 2019, 191, E932-E939.	2.0	14
74	From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness. <i>Preventive Medicine</i> , 2021, 144, 106354.	3.4	12
75	An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. <i>Vaccine</i> , 2019, 37, 4376-4381.	3.8	11
76	The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018. <i>Sexually Transmitted Diseases</i> , 2021, 48, 278-284.	1.7	11
77	Epidemiology of varicella among immigrants and non-immigrants in Quebec, Canada, before and after the introduction of childhood varicella vaccination: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 116-126.	9.1	8
78	Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?. <i>PLoS ONE</i> , 2013, 8, e67072.	2.5	5
79	Fewer than three doses of HPV vaccine. <i>Lancet Oncology</i> , The, 2015, 16, e423-e424.	10.7	5
80	Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. <i>Vaccine</i> , 2021, 39, 871-875.	3.8	5
81	Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam. <i>International Journal of Infectious Diseases</i> , 2021, 112, 136-143.	3.3	5
82	Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting. <i>International Journal of Cancer</i> , 2022, 151, 1804-1809.	5.1	4
83	Effect of HPV on cervical cancer screening in Alberta. <i>Cmaj</i> , 2016, 188, 1035.1-1035.	2.0	2
84	Response. <i>Journal of the National Cancer Institute</i> , 2013, 105, 750-751.	6.3	1
85	Response. <i>Journal of the National Cancer Institute</i> , 2013, 105, 664-665.	6.3	1
86	HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg. <i>PeerJ</i> , 2020, 8, e8516.	2.0	1
87	2301. Increased Risk of Varicella-Associated Hospitalizations Among Adult Immigrants From Temperate and Tropical Countries After the Introduction of a Childhood Varicella Vaccination Program in Quebec, Canada. <i>Open Forum Infectious Diseases</i> , 2019, 6, S788-S788.	0.9	0
88	Population-level impact of human papillomavirus vaccination – Authors' reply. <i>Lancet</i> , The, 2020, 395, 412-413.	18.7	0